David Fleischer
Concepts (469)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 58 | 2025 | 147 | 14.150 |
Why?
| | Food Hypersensitivity | 52 | 2025 | 182 | 10.260 |
Why?
| | Arachis | 45 | 2025 | 112 | 9.320 |
Why?
| | Allergens | 58 | 2025 | 397 | 8.370 |
Why?
| | Desensitization, Immunologic | 31 | 2025 | 95 | 6.190 |
Why?
| | Infant Nutritional Physiological Phenomena | 12 | 2025 | 144 | 2.870 |
Why?
| | Anaphylaxis | 13 | 2025 | 107 | 2.690 |
Why?
| | Immunoglobulin E | 33 | 2025 | 328 | 2.280 |
Why?
| | Diet | 18 | 2024 | 1285 | 2.250 |
Why?
| | Dermatitis, Atopic | 15 | 2025 | 331 | 1.960 |
Why?
| | Milk Hypersensitivity | 8 | 2024 | 19 | 1.580 |
Why?
| | Transdermal Patch | 3 | 2020 | 15 | 1.430 |
Why?
| | Eosinophilic Esophagitis | 10 | 2021 | 325 | 1.420 |
Why?
| | Epinephrine | 5 | 2025 | 145 | 1.370 |
Why?
| | Skin Tests | 20 | 2025 | 97 | 1.360 |
Why?
| | Plant Proteins | 4 | 2025 | 110 | 1.160 |
Why?
| | Esophagoscopy | 13 | 2022 | 210 | 1.140 |
Why?
| | Immunotherapy | 9 | 2024 | 633 | 1.110 |
Why?
| | Primary Prevention | 5 | 2022 | 199 | 1.110 |
Why?
| | Hypersensitivity | 4 | 2025 | 254 | 1.050 |
Why?
| | Infant | 47 | 2025 | 9577 | 1.040 |
Why?
| | Antigens, Plant | 7 | 2025 | 54 | 1.040 |
Why?
| | Egg Hypersensitivity | 11 | 2019 | 29 | 0.960 |
Why?
| | Humans | 171 | 2025 | 138972 | 0.950 |
Why?
| | Administration, Cutaneous | 11 | 2025 | 128 | 0.940 |
Why?
| | Gastrointestinal Diseases | 9 | 2019 | 208 | 0.930 |
Why?
| | Infant Formula | 4 | 2023 | 73 | 0.930 |
Why?
| | Child | 60 | 2025 | 21936 | 0.920 |
Why?
| | Child, Preschool | 39 | 2025 | 11158 | 0.880 |
Why?
| | Nut Hypersensitivity | 3 | 2010 | 5 | 0.850 |
Why?
| | Noncommunicable Diseases | 1 | 2023 | 18 | 0.820 |
Why?
| | Breast Feeding | 8 | 2023 | 434 | 0.810 |
Why?
| | Protein Hydrolysates | 3 | 2018 | 6 | 0.770 |
Why?
| | Anti-Allergic Agents | 5 | 2024 | 41 | 0.750 |
Why?
| | Eczema | 10 | 2022 | 69 | 0.750 |
Why?
| | Hypersensitivity, Immediate | 3 | 2023 | 42 | 0.730 |
Why?
| | Endoscopy, Gastrointestinal | 7 | 2022 | 229 | 0.710 |
Why?
| | Immune Tolerance | 9 | 2023 | 366 | 0.680 |
Why?
| | Asthma | 9 | 2025 | 1893 | 0.680 |
Why?
| | Esophageal Stenosis | 6 | 2015 | 55 | 0.620 |
Why?
| | Esophageal Neoplasms | 10 | 2022 | 328 | 0.620 |
Why?
| | Double-Blind Method | 15 | 2025 | 1949 | 0.620 |
Why?
| | Female | 76 | 2025 | 74016 | 0.610 |
Why?
| | Schools | 4 | 2021 | 449 | 0.600 |
Why?
| | Omalizumab | 3 | 2024 | 40 | 0.540 |
Why?
| | Male | 64 | 2025 | 68250 | 0.520 |
Why?
| | Gastroenterology | 2 | 2015 | 176 | 0.490 |
Why?
| | Eosinophilia | 4 | 2013 | 218 | 0.490 |
Why?
| | Administration, Oral | 9 | 2022 | 787 | 0.480 |
Why?
| | Practice Guidelines as Topic | 10 | 2024 | 1569 | 0.470 |
Why?
| | Nasal Sprays | 2 | 2025 | 5 | 0.460 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 372 | 0.460 |
Why?
| | Coronavirus Infections | 4 | 2020 | 369 | 0.450 |
Why?
| | Lye | 1 | 2014 | 1 | 0.440 |
Why?
| | Caustics | 1 | 2014 | 7 | 0.440 |
Why?
| | Dilatation | 2 | 2014 | 67 | 0.430 |
Why?
| | Endosonography | 1 | 2015 | 152 | 0.430 |
Why?
| | Burns, Chemical | 1 | 2014 | 32 | 0.430 |
Why?
| | Adolescent | 25 | 2025 | 21581 | 0.420 |
Why?
| | Barrett Esophagus | 3 | 2022 | 154 | 0.410 |
Why?
| | Feeding Behavior | 3 | 2019 | 685 | 0.400 |
Why?
| | Betacoronavirus | 3 | 2020 | 273 | 0.400 |
Why?
| | Food | 5 | 2024 | 165 | 0.380 |
Why?
| | Pandemics | 5 | 2020 | 1645 | 0.380 |
Why?
| | Environmental Exposure | 1 | 2017 | 569 | 0.370 |
Why?
| | Gastrointestinal Hemorrhage | 4 | 2007 | 130 | 0.360 |
Why?
| | Cattle | 4 | 2024 | 990 | 0.350 |
Why?
| | Allergy and Immunology | 3 | 2020 | 41 | 0.340 |
Why?
| | Infant Food | 2 | 2023 | 64 | 0.340 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1522 | 0.340 |
Why?
| | Consensus | 7 | 2024 | 683 | 0.330 |
Why?
| | Esophagus | 8 | 2019 | 257 | 0.330 |
Why?
| | Treatment Outcome | 13 | 2025 | 10921 | 0.330 |
Why?
| | Adenocarcinoma | 5 | 2022 | 882 | 0.320 |
Why?
| | United States | 24 | 2024 | 15074 | 0.320 |
Why?
| | Milk Proteins | 3 | 2024 | 34 | 0.320 |
Why?
| | Allergists | 3 | 2020 | 11 | 0.320 |
Why?
| | Endoscopy | 7 | 2018 | 320 | 0.310 |
Why?
| | Risk | 5 | 2018 | 913 | 0.300 |
Why?
| | Virtual Reality | 2 | 2021 | 65 | 0.300 |
Why?
| | Young Adult | 13 | 2025 | 13371 | 0.280 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 18 | 0.270 |
Why?
| | Intestinal Diseases | 1 | 2007 | 42 | 0.270 |
Why?
| | Adult | 26 | 2025 | 38393 | 0.270 |
Why?
| | Enterocolitis | 2 | 2020 | 17 | 0.260 |
Why?
| | Colonoscopy | 4 | 2014 | 245 | 0.260 |
Why?
| | Severity of Illness Index | 6 | 2019 | 2849 | 0.260 |
Why?
| | Adrenal Cortex Hormones | 3 | 2017 | 496 | 0.250 |
Why?
| | Brazil | 2 | 2023 | 166 | 0.250 |
Why?
| | Time Factors | 7 | 2020 | 6869 | 0.250 |
Why?
| | Capsules | 2 | 2005 | 39 | 0.250 |
Why?
| | Rhinitis, Allergic | 3 | 2022 | 42 | 0.240 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 7 | 2019 | 25 | 0.240 |
Why?
| | Pregnancy | 9 | 2024 | 6870 | 0.230 |
Why?
| | Administration, Sublingual | 3 | 2016 | 12 | 0.220 |
Why?
| | Canada | 3 | 2020 | 408 | 0.220 |
Why?
| | Immunomodulation | 2 | 2018 | 99 | 0.220 |
Why?
| | Age Factors | 7 | 2018 | 3276 | 0.220 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2000 | 75 | 0.220 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5152 | 0.210 |
Why?
| | Healthy Volunteers | 2 | 2024 | 208 | 0.210 |
Why?
| | Diagnostic Imaging | 2 | 2006 | 320 | 0.210 |
Why?
| | Catheter Ablation | 2 | 2019 | 302 | 0.210 |
Why?
| | Constipation | 1 | 2024 | 98 | 0.200 |
Why?
| | Eosinophils | 2 | 2018 | 322 | 0.200 |
Why?
| | Laser Therapy | 5 | 1985 | 127 | 0.200 |
Why?
| | Intestinal Mucosa | 2 | 2015 | 620 | 0.190 |
Why?
| | Cross-Over Studies | 1 | 2024 | 555 | 0.190 |
Why?
| | Food Analysis | 1 | 2022 | 26 | 0.180 |
Why?
| | Middle Aged | 22 | 2025 | 33782 | 0.180 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 35 | 0.180 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 242 | 0.180 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2030 | 0.180 |
Why?
| | Animals | 13 | 2024 | 37243 | 0.180 |
Why?
| | Milk | 3 | 2018 | 123 | 0.170 |
Why?
| | Child Day Care Centers | 1 | 2021 | 36 | 0.170 |
Why?
| | Dietary Exposure | 1 | 2020 | 6 | 0.170 |
Why?
| | Aptamers, Nucleotide | 1 | 2022 | 83 | 0.170 |
Why?
| | Restaurants | 1 | 2020 | 25 | 0.170 |
Why?
| | Diet Therapy | 2 | 2017 | 37 | 0.170 |
Why?
| | Infusions, Subcutaneous | 1 | 2020 | 23 | 0.170 |
Why?
| | Eggs | 2 | 2018 | 26 | 0.160 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 105 | 0.160 |
Why?
| | Deglutition Disorders | 2 | 2019 | 148 | 0.160 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 383 | 0.160 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 611 | 0.160 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1482 | 0.160 |
Why?
| | Europe | 2 | 2022 | 407 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 122 | 0.150 |
Why?
| | Immunization | 3 | 2017 | 405 | 0.150 |
Why?
| | Prevalence | 4 | 2024 | 2745 | 0.150 |
Why?
| | Quality of Life | 6 | 2022 | 2962 | 0.150 |
Why?
| | Multiphasic Screening | 1 | 2018 | 1 | 0.150 |
Why?
| | United Kingdom | 4 | 2020 | 321 | 0.140 |
Why?
| | Confidence Intervals | 1 | 2019 | 335 | 0.140 |
Why?
| | Population Groups | 1 | 2018 | 59 | 0.140 |
Why?
| | Blood Pressure | 1 | 2025 | 1737 | 0.140 |
Why?
| | Meta-Analysis as Topic | 2 | 2016 | 186 | 0.140 |
Why?
| | Food, Genetically Modified | 1 | 2017 | 2 | 0.140 |
Why?
| | Coal Tar | 1 | 2017 | 2 | 0.140 |
Why?
| | Keratolytic Agents | 1 | 2017 | 5 | 0.140 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 246 | 0.140 |
Why?
| | Skin Cream | 1 | 2017 | 12 | 0.140 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2017 | 5 | 0.140 |
Why?
| | Plants, Genetically Modified | 1 | 2017 | 15 | 0.140 |
Why?
| | Emollients | 1 | 2017 | 11 | 0.140 |
Why?
| | Baths | 1 | 2017 | 14 | 0.140 |
Why?
| | Health Promotion | 1 | 2024 | 750 | 0.140 |
Why?
| | Histamine Antagonists | 1 | 2017 | 20 | 0.140 |
Why?
| | Clothing | 1 | 2017 | 22 | 0.140 |
Why?
| | Crops, Agricultural | 1 | 2017 | 30 | 0.140 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 280 | 0.130 |
Why?
| | Calcineurin Inhibitors | 1 | 2017 | 70 | 0.130 |
Why?
| | School Health Services | 1 | 2020 | 231 | 0.130 |
Why?
| | Telemedicine | 3 | 2020 | 876 | 0.130 |
Why?
| | Risk Assessment | 4 | 2019 | 3466 | 0.130 |
Why?
| | Mothers | 1 | 2023 | 765 | 0.130 |
Why?
| | Prognosis | 2 | 2020 | 3995 | 0.130 |
Why?
| | Nutritionists | 1 | 2016 | 19 | 0.130 |
Why?
| | Kidney Transplantation | 1 | 2022 | 658 | 0.130 |
Why?
| | Basophils | 2 | 2015 | 72 | 0.120 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 132 | 0.120 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 107 | 0.120 |
Why?
| | Eating | 1 | 2019 | 394 | 0.120 |
Why?
| | Bottle Feeding | 1 | 2016 | 20 | 0.120 |
Why?
| | Infant, Newborn | 6 | 2024 | 6158 | 0.120 |
Why?
| | Indonesia | 1 | 2015 | 24 | 0.120 |
Why?
| | Palliative Care | 4 | 2010 | 815 | 0.120 |
Why?
| | Health Care Reform | 2 | 1994 | 106 | 0.120 |
Why?
| | Surveys and Questionnaires | 7 | 2024 | 5884 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2020 | 427 | 0.120 |
Why?
| | Nutritional Requirements | 1 | 2016 | 81 | 0.120 |
Why?
| | Biological Products | 1 | 2018 | 226 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2022 | 1149 | 0.120 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.110 |
Why?
| | Sublingual Immunotherapy | 1 | 2015 | 5 | 0.110 |
Why?
| | Aging | 1 | 2005 | 1857 | 0.110 |
Why?
| | Probiotics | 1 | 2015 | 56 | 0.110 |
Why?
| | Carcinoma in Situ | 1 | 2015 | 44 | 0.110 |
Why?
| | Fluticasone | 1 | 2015 | 56 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 214 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2019 | 560 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 637 | 0.110 |
Why?
| | History, 20th Century | 1 | 2015 | 324 | 0.110 |
Why?
| | Biopsy | 5 | 2019 | 1072 | 0.110 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 1811 | 0.110 |
Why?
| | Coloring Agents | 2 | 2015 | 95 | 0.110 |
Why?
| | Wrist Injuries | 1 | 2014 | 23 | 0.100 |
Why?
| | Cumulative Trauma Disorders | 1 | 2014 | 30 | 0.100 |
Why?
| | Risk Factors | 7 | 2019 | 10385 | 0.100 |
Why?
| | Premedication | 3 | 1990 | 41 | 0.100 |
Why?
| | Caregivers | 2 | 2020 | 904 | 0.100 |
Why?
| | Prospective Studies | 8 | 2019 | 7661 | 0.100 |
Why?
| | Wrist Joint | 1 | 2014 | 71 | 0.100 |
Why?
| | Occupational Injuries | 1 | 2014 | 44 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 609 | 0.100 |
Why?
| | Information Systems | 1 | 1993 | 61 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 930 | 0.100 |
Why?
| | Family | 2 | 2015 | 680 | 0.100 |
Why?
| | Epitopes | 2 | 2025 | 475 | 0.100 |
Why?
| | Posture | 2 | 2014 | 192 | 0.100 |
Why?
| | Patient Education as Topic | 2 | 2015 | 766 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 743 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 963 | 0.100 |
Why?
| | Societies, Medical | 2 | 1994 | 835 | 0.100 |
Why?
| | Sympathomimetics | 1 | 2012 | 19 | 0.100 |
Why?
| | Disease Progression | 5 | 2019 | 2752 | 0.100 |
Why?
| | Mucositis | 1 | 2012 | 20 | 0.100 |
Why?
| | Poisson Distribution | 1 | 2012 | 77 | 0.090 |
Why?
| | Pregnenediones | 1 | 2012 | 15 | 0.090 |
Why?
| | Recurrence | 3 | 2004 | 1085 | 0.090 |
Why?
| | Health Surveys | 2 | 2012 | 520 | 0.090 |
Why?
| | Disease Management | 3 | 2024 | 621 | 0.090 |
Why?
| | Patient Compliance | 2 | 2016 | 602 | 0.090 |
Why?
| | Oximetry | 2 | 1990 | 118 | 0.090 |
Why?
| | Cohort Studies | 5 | 2022 | 5744 | 0.090 |
Why?
| | Child Development | 1 | 2016 | 471 | 0.090 |
Why?
| | Self Care | 1 | 2014 | 387 | 0.090 |
Why?
| | Bacterial Proteins | 1 | 2017 | 898 | 0.090 |
Why?
| | Stents | 3 | 2000 | 526 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2015 | 689 | 0.090 |
Why?
| | Biomarkers | 2 | 2020 | 4095 | 0.090 |
Why?
| | Symptom Assessment | 1 | 2012 | 129 | 0.080 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2010 | 7 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1008 | 0.080 |
Why?
| | Metaplasia | 2 | 2022 | 58 | 0.080 |
Why?
| | Immunoassay | 1 | 2010 | 111 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1321 | 0.080 |
Why?
| | Cathartics | 1 | 1990 | 15 | 0.080 |
Why?
| | Health Policy | 1 | 1993 | 398 | 0.080 |
Why?
| | Citrates | 1 | 1990 | 41 | 0.080 |
Why?
| | Flavoring Agents | 1 | 1990 | 13 | 0.080 |
Why?
| | Phenotype | 1 | 2018 | 3143 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2022 | 243 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 1021 | 0.080 |
Why?
| | Adaptation, Psychological | 1 | 2015 | 675 | 0.080 |
Why?
| | Diet Surveys | 2 | 2024 | 95 | 0.080 |
Why?
| | Duodenoscopy | 1 | 1989 | 7 | 0.080 |
Why?
| | Gastroscopy | 1 | 1989 | 18 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2014 | 1103 | 0.080 |
Why?
| | Food, Formulated | 1 | 2009 | 15 | 0.080 |
Why?
| | Drainage | 1 | 2010 | 172 | 0.080 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2013 | 347 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 15901 | 0.070 |
Why?
| | Lasers | 3 | 1985 | 129 | 0.070 |
Why?
| | Maternal Exposure | 1 | 2010 | 189 | 0.070 |
Why?
| | Physician-Patient Relations | 1 | 1993 | 581 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1244 | 0.070 |
Why?
| | Light Coagulation | 1 | 1988 | 9 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 814 | 0.070 |
Why?
| | Physical Examination | 1 | 2009 | 240 | 0.070 |
Why?
| | Cholestasis | 1 | 2010 | 208 | 0.070 |
Why?
| | Precancerous Conditions | 2 | 2019 | 165 | 0.070 |
Why?
| | Digestive System | 2 | 2002 | 28 | 0.070 |
Why?
| | Hypnotics and Sedatives | 1 | 1989 | 211 | 0.060 |
Why?
| | Feces | 1 | 1990 | 481 | 0.060 |
Why?
| | Aged | 15 | 2019 | 24172 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1437 | 0.060 |
Why?
| | Risk Reduction Behavior | 2 | 2019 | 216 | 0.060 |
Why?
| | Immunologic Tests | 1 | 2005 | 16 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 40 | 0.060 |
Why?
| | Sepsis | 2 | 1989 | 611 | 0.060 |
Why?
| | Comorbidity | 2 | 2025 | 1657 | 0.060 |
Why?
| | Equipment Safety | 1 | 2005 | 37 | 0.060 |
Why?
| | Equipment Design | 2 | 2005 | 518 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3313 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 475 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1939 | 0.060 |
Why?
| | Dietetics | 2 | 2017 | 27 | 0.060 |
Why?
| | Esophageal and Gastric Varices | 1 | 1985 | 35 | 0.060 |
Why?
| | Administration, Intranasal | 1 | 2024 | 91 | 0.050 |
Why?
| | Immunoglobulin G | 3 | 2014 | 898 | 0.050 |
Why?
| | Procainamide | 1 | 1984 | 6 | 0.050 |
Why?
| | Hyperplasia | 2 | 2022 | 176 | 0.050 |
Why?
| | Injections, Intramuscular | 1 | 2024 | 131 | 0.050 |
Why?
| | Nutrition Assessment | 1 | 2024 | 93 | 0.050 |
Why?
| | Therapeutic Irrigation | 1 | 1984 | 79 | 0.050 |
Why?
| | Pollen | 1 | 2023 | 22 | 0.050 |
Why?
| | Intestinal Absorption | 1 | 1984 | 92 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 55 | 0.050 |
Why?
| | Turkey | 1 | 2022 | 21 | 0.050 |
Why?
| | Digestive System Diseases | 1 | 2002 | 26 | 0.050 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2024 | 177 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 290 | 0.050 |
Why?
| | Vitamins | 1 | 2024 | 188 | 0.050 |
Why?
| | Software | 1 | 2007 | 670 | 0.050 |
Why?
| | Immunity | 1 | 2023 | 141 | 0.050 |
Why?
| | Metals | 2 | 2000 | 140 | 0.050 |
Why?
| | Hemoglobinuria, Paroxysmal | 1 | 2002 | 6 | 0.050 |
Why?
| | HLA Antigens | 1 | 2022 | 233 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4316 | 0.040 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2020 | 28 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2021 | 109 | 0.040 |
Why?
| | Injections | 1 | 2021 | 190 | 0.040 |
Why?
| | Educational Personnel | 1 | 2020 | 11 | 0.040 |
Why?
| | Terbutaline | 1 | 2020 | 9 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 209 | 0.040 |
Why?
| | Japan | 1 | 2000 | 128 | 0.040 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2000 | 14 | 0.040 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2000 | 29 | 0.040 |
Why?
| | Albuterol | 1 | 2020 | 74 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 197 | 0.040 |
Why?
| | China | 1 | 2000 | 214 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2020 | 72 | 0.040 |
Why?
| | Food Contamination | 1 | 2019 | 55 | 0.040 |
Why?
| | Interprofessional Relations | 2 | 1994 | 290 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2018 | 85 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 117 | 0.040 |
Why?
| | Esophagogastric Junction | 1 | 2019 | 52 | 0.040 |
Why?
| | Intestines | 1 | 2002 | 356 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 571 | 0.040 |
Why?
| | Ischemia | 1 | 2002 | 414 | 0.040 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 25 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2362 | 0.040 |
Why?
| | New Zealand | 1 | 2018 | 55 | 0.040 |
Why?
| | Efferent Pathways | 1 | 1998 | 19 | 0.040 |
Why?
| | Psychometrics | 1 | 2022 | 730 | 0.040 |
Why?
| | Food Labeling | 1 | 2017 | 15 | 0.030 |
Why?
| | Locus Coeruleus | 1 | 1998 | 22 | 0.030 |
Why?
| | Hydrolysis | 1 | 2018 | 194 | 0.030 |
Why?
| | Markov Chains | 1 | 2018 | 126 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 359 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 59 | 0.030 |
Why?
| | Cross Reactions | 1 | 2017 | 130 | 0.030 |
Why?
| | Immune Sera | 1 | 2017 | 83 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2019 | 134 | 0.030 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.030 |
Why?
| | Metiamide | 1 | 1977 | 1 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 684 | 0.030 |
Why?
| | Thiourea | 1 | 1977 | 41 | 0.030 |
Why?
| | Agranulocytosis | 1 | 1977 | 32 | 0.030 |
Why?
| | Guanidines | 1 | 1977 | 41 | 0.030 |
Why?
| | Australia | 1 | 2018 | 307 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 567 | 0.030 |
Why?
| | Norepinephrine | 1 | 1998 | 192 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2017 | 51 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 187 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2016 | 33 | 0.030 |
Why?
| | Uncertainty | 1 | 2017 | 130 | 0.030 |
Why?
| | Protective Factors | 1 | 2017 | 96 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 44 | 0.030 |
Why?
| | Transgenes | 1 | 2017 | 185 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2017 | 191 | 0.030 |
Why?
| | Probability | 1 | 2017 | 308 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 22 | 0.030 |
Why?
| | Incidence | 2 | 2019 | 2830 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 162 | 0.030 |
Why?
| | Imidazoles | 1 | 1977 | 239 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2233 | 0.030 |
Why?
| | Iodides | 1 | 2015 | 11 | 0.030 |
Why?
| | Radio Waves | 1 | 2015 | 17 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 87 | 0.030 |
Why?
| | Mass Screening | 2 | 2019 | 1296 | 0.030 |
Why?
| | Mice | 1 | 2011 | 17828 | 0.030 |
Why?
| | Endoscopes | 2 | 1985 | 17 | 0.030 |
Why?
| | Calpain | 1 | 2014 | 59 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1985 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2012 | 2850 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 305 | 0.030 |
Why?
| | Synapses | 1 | 1998 | 426 | 0.030 |
Why?
| | Treatment Failure | 1 | 2015 | 351 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 310 | 0.030 |
Why?
| | Steroids | 1 | 2014 | 163 | 0.030 |
Why?
| | Population Surveillance | 1 | 2017 | 482 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2014 | 148 | 0.030 |
Why?
| | Public Opinion | 1 | 1993 | 67 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2000 | 754 | 0.020 |
Why?
| | Eosinophil Granule Proteins | 1 | 2012 | 15 | 0.020 |
Why?
| | Lysophospholipase | 1 | 2012 | 10 | 0.020 |
Why?
| | Aged, 80 and over | 5 | 2010 | 7685 | 0.020 |
Why?
| | Haplotypes | 1 | 2014 | 497 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1058 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2012 | 21 | 0.020 |
Why?
| | Forecasting | 1 | 1994 | 384 | 0.020 |
Why?
| | Biomedical Research | 1 | 2018 | 695 | 0.020 |
Why?
| | Survival Rate | 2 | 2010 | 1934 | 0.020 |
Why?
| | Movement | 1 | 2014 | 281 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2012 | 126 | 0.020 |
Why?
| | Models, Genetic | 1 | 2014 | 591 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 409 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 852 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 856 | 0.020 |
Why?
| | Abdominal Pain | 2 | 2002 | 142 | 0.020 |
Why?
| | Specimen Handling | 1 | 2012 | 182 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3984 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 521 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2022 | 2716 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 817 | 0.020 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 1990 | 9 | 0.020 |
Why?
| | Professional Role | 1 | 2012 | 168 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 354 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2012 | 704 | 0.020 |
Why?
| | Gallbladder Neoplasms | 1 | 2010 | 19 | 0.020 |
Why?
| | Midazolam | 1 | 1990 | 69 | 0.020 |
Why?
| | Citric Acid | 1 | 1990 | 32 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1989 | 45 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 214 | 0.020 |
Why?
| | Computer Simulation | 1 | 2014 | 995 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1849 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 990 | 0.020 |
Why?
| | Health Status | 1 | 2014 | 823 | 0.020 |
Why?
| | Cholangiocarcinoma | 1 | 2010 | 93 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5530 | 0.020 |
Why?
| | Neurons | 1 | 1998 | 1602 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2010 | 115 | 0.020 |
Why?
| | Pancreatic Neoplasms | 2 | 2010 | 859 | 0.020 |
Why?
| | Pneumoperitoneum | 1 | 1988 | 11 | 0.020 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1988 | 20 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2014 | 1391 | 0.020 |
Why?
| | Social Support | 1 | 2012 | 628 | 0.020 |
Why?
| | Electrocoagulation | 1 | 1987 | 35 | 0.020 |
Why?
| | Anxiety | 1 | 2015 | 1070 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 969 | 0.020 |
Why?
| | Anesthesiology | 1 | 1990 | 159 | 0.020 |
Why?
| | Electrocardiography | 1 | 1990 | 610 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 1079 | 0.020 |
Why?
| | Gastrostomy | 1 | 1988 | 118 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2015 | 1124 | 0.020 |
Why?
| | Duodenal Ulcer | 1 | 1985 | 13 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1423 | 0.020 |
Why?
| | Drug Design | 1 | 2006 | 165 | 0.010 |
Why?
| | Genetic Markers | 1 | 2006 | 344 | 0.010 |
Why?
| | Arteriovenous Malformations | 1 | 1985 | 28 | 0.010 |
Why?
| | Hemostatic Techniques | 1 | 1985 | 49 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1985 | 175 | 0.010 |
Why?
| | Health Services Accessibility | 1 | 2012 | 993 | 0.010 |
Why?
| | Random Allocation | 1 | 1985 | 362 | 0.010 |
Why?
| | Electrolytes | 1 | 1984 | 55 | 0.010 |
Why?
| | Stomach Neoplasms | 1 | 1985 | 117 | 0.010 |
Why?
| | Quinidine | 1 | 1983 | 5 | 0.010 |
Why?
| | Streptococcal Infections | 1 | 1985 | 150 | 0.010 |
Why?
| | Tablets | 1 | 1983 | 41 | 0.010 |
Why?
| | Cholelithiasis | 1 | 2002 | 37 | 0.010 |
Why?
| | Gallstones | 1 | 2002 | 33 | 0.010 |
Why?
| | Biliary Tract Neoplasms | 1 | 2002 | 29 | 0.010 |
Why?
| | Colonic Diseases | 1 | 1982 | 34 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 792 | 0.010 |
Why?
| | Iran | 1 | 2002 | 43 | 0.010 |
Why?
| | Jejunum | 1 | 2002 | 32 | 0.010 |
Why?
| | Pancreatitis | 1 | 2002 | 133 | 0.010 |
Why?
| | Duodenum | 1 | 2002 | 74 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 187 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 441 | 0.010 |
Why?
| | Dogs | 1 | 1982 | 425 | 0.010 |
Why?
| | Rectal Neoplasms | 1 | 1982 | 143 | 0.010 |
Why?
| | Age Distribution | 1 | 2002 | 401 | 0.010 |
Why?
| | Sex Distribution | 1 | 2002 | 380 | 0.010 |
Why?
| | Granulation Tissue | 1 | 2000 | 7 | 0.010 |
Why?
| | Foreign-Body Reaction | 1 | 2000 | 32 | 0.010 |
Why?
| | Pruritus | 1 | 2000 | 64 | 0.010 |
Why?
| | Equipment Failure Analysis | 1 | 2000 | 131 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 993 | 0.010 |
Why?
| | Aspirin | 1 | 1983 | 390 | 0.010 |
Why?
| | Axonal Transport | 1 | 1998 | 26 | 0.010 |
Why?
| | Neuropeptides | 1 | 1998 | 75 | 0.010 |
Why?
| | Fibrosis | 1 | 2000 | 539 | 0.010 |
Why?
| | Neurons, Afferent | 1 | 1998 | 98 | 0.010 |
Why?
| | Tracheoesophageal Fistula | 1 | 1997 | 33 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2000 | 426 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2000 | 1370 | 0.010 |
Why?
| | Brain Mapping | 1 | 1998 | 523 | 0.010 |
Why?
| | False Positive Reactions | 1 | 1988 | 124 | 0.000 |
Why?
| | Peptococcus | 1 | 1985 | 1 | 0.000 |
Why?
| | Radiography | 1 | 1988 | 839 | 0.000 |
Why?
| | Drinking | 1 | 1983 | 42 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 1034 | 0.000 |
Why?
| | Deglutition | 1 | 1983 | 71 | 0.000 |
Why?
| | Esophagitis | 1 | 1983 | 68 | 0.000 |
Why?
| | Pilot Projects | 1 | 1987 | 1765 | 0.000 |
Why?
|
|
Fleischer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|